Keeping pace with generative AI in pharmaceutical and healthcare organisations
Increasingly, generative AI is transforming how that information is analysed, summarised and shared. According to 2026 research by the Copyright Licensing …
Post
-
-
Roche culls development of two Huntington’s disease programmes
Roche has stopped development of two of its Huntington’s disease candidates after one failed to show benefit in a Phase …
-
Ipsen set to rival Botox after duo of Phase III migraine wins
Ipsen Pharmaceuticals’ Dysport (abobotulinumtoxinA), a Botox (onabotulinumtoxinA) competitor, could be on track for a label expansion after the drug posted …
-
Forte Biosciences reports positive results from Phase Ib trial for vitiligo
Forte Biosciences has reported positive results from its double-blind, placebo-controlled Phase Ib trial assessing FB102 for vitiligo. The study followed patients …
-
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial
Quoin Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application …
-
AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure
Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced that a …
-
Keenova seeks Xiaflex expansion on late-stage rare disease win
Keenova Therapeutics is hoping to step into a new market with Xiaflex (collagenase clostridium histolyticum), after the drug netted a …
-
Satellos’ oral DMD drug improves arm movement after six months in Phase II
Satellos Bioscience’s oral Duchenne muscular dystrophy (DMD) drug has increased upper limb activity in four patients in a Phase II …
-
MAIA reports positive efficacy results from Phase II trial for NSCLC
MAIA Biotechnology has reported positive initial efficacy results from its Phase II THIO-101 trial, Part C, involving its lead candidate, …
-
First patient receives Forzinity in Mighty Therapeutics’ Phase IV study
Mighty Therapeutics has dosed the first patient in 4TAZPower, its global Phase IV confirmatory study assessing Forzinity (elamipretide) injection in …
-
Addressing sexual minority gaps in cervical and breast cancer screening
According to the US Centers for Disease Control and Prevention (CDC), over 43,000 females and 4,000 females died from breast …
-
Turn Therapeutics’ stock jumps on AD data and trial expansion
Turn Therapeutics’ stock has jumped by 26% after its atopic dermatitis (AD) candidate boasted clinically meaningful efficacy in a Phase …
-
Teva draws up mid-stage study plans for vitiligo asset on Phase Ib success
Teva is planning to progress its anti-IL-15 therapy, TEV-‘408 into a Phase IIb trial in vitiligo after the drug demonstrated …
-
Bayer enters clinical trials alliance with CU Anschutz and partners
Bayer has entered a strategic alliance with the University of Colorado Anschutz (CU Anschutz), UCHealth, and Children’s Hospital Colorado, with …
-
Prilenia and Ferrer begin Phase III trial of Huntington’s therapy
Prilenia Therapeutics and Ferrer have begun the confirmatory Phase III PRECISE-HD clinical trial assessing pridopidine as a potential treatment for …
